Don't get left behind! The modernized ClinicalTrials.gov is coming. Check it out now.
Say goodbye to ClinicalTrials.gov!
The new site is coming soon - go to the modernized ClinicalTrials.gov
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04336254
Recruitment Status : Unknown
Verified March 2021 by Ye Qingsong, Renmin Hospital of Wuhan University.
Recruitment status was:  Recruiting
First Posted : April 7, 2020
Last Update Posted : March 10, 2021
Sponsor:
Collaborators:
Beijing SH Bio-Tech Corporation, Beijing (CN)
Utooth Biological Technology Co., Ltd. Hubei (CN)
Information provided by (Responsible Party):
Ye Qingsong, Renmin Hospital of Wuhan University

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This clinical trial is set out to evaluate the safety and efficacy of allogeneic human dental pulp mesenchymal stem cells in the treatment of severe pneumonia caused by COVID-19; to explore the effects of human dental pulp mesenchymal stem cells in the treatment of severe pneumonia of COVID-19 in terms of reducing mortality and improving clinical prognosis; and to discover a new therapeutic strategy for COVID-19 using allogeneic human dental pulp mesenchymal stem cells.

Condition or disease Intervention/treatment Phase
COVID-19 Biological: allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC) Other: Intravenous saline injection (Placebo) Phase 1 Phase 2

Detailed Description:

This clinical trial is set out to evaluate the followings:

  1. the safety and efficacy of allogeneic human dental pulp mesenchymal stem cells in the treatment of severe pneumonia caused by COVID-19;
  2. to explore the effects of human dental pulp mesenchymal stem cells in the treatment of severe pneumonia of COVID-19 in terms of reducing mortality and improving clinical prognosis; and
  3. to discover a new therapeutic strategy for COVID-19 using allogeneic human dental pulp mesenchymal stem cells.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe Pneumonia of COVID-19：a Single-center, Prospective, Randomised Clinical Trial
Actual Study Start Date : May 6, 2020
Estimated Primary Completion Date : November 30, 2021
Estimated Study Completion Date : December 31, 2021

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: hDPSCs group
Routine treatment + Intravenous injection of human dental pulp stem cells
 Biological: allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC)
Intravenous injection of 3.0x10e7 human dental pulp stem cells solution (30ml) on day 1, day 4 and day 7, based on routine treatment of COVID-19
Placebo Comparator: Control group
Routine treatment + Intravenous saline injection (Placebo)
 Other: Intravenous saline injection (Placebo)
Intravenous injection of 3ml of 0.9% saline on day 1, day 4 and day 7, based on routine treatment of COVID-19


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. TTCI [ Time Frame: 1-28 days ]
    Time to Clinical Improvement


Secondary Outcome Measures :
  1. Lung lesion [ Time Frame: 1-28 days ]
    Lung Lesion by CT

  2. Immune function [ Time Frame: 1-28 days ]
    1. Th1 cytokines: IL-1β, IL- 2, TNF-a, ITN-γ;
    2. Th2 cytokines: IL- 4, IL- 6, IL- 10;
    3. Immunoglobulins: IgA, IgG, IgM, and total IgE;
    4. Lymphocyte counts: CD3+, CD4+, CD8+, CD16+,CD19+, CD56+.

  3. Time of SARS-CoV-2 clearance [ Time Frame: 1-28 days ]
    Time of SARS-CoV-2 test turns negative

  4. Blood test [ Time Frame: 1-28 days ]
    Blood cell count and classification

  5. SPO2 [ Time Frame: 1-28 days ]
    Pulse oximetry

  6. RR [ Time Frame: 1-28 days ]
    Respiratory rate

  7. Body temperature [ Time Frame: 1-28 days ]
    Body temperature

  8. Side effects in the treatment group [ Time Frame: 1-28 days ]
    Number of the included patients with hDPSCs-related adverse events, e.g. liver or kidney function failure

  9. C-reactive protein (mg/L) [ Time Frame: 1-28 days ]
    C-reactive protein in microgram per litre


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Aged 18-65 years;
  2. Voluntarily participate in this clinical trial and sign off "informed consent form";
  3. Diagnosed with severe pneumonia of COVID: respiratory distress, RR >30 times / min; resting oxygen saturation of 93% or less; arterial partial pressure of oxygen / oxygen concentration 300mmHg; SARS-CoV-2 nucleic acid test was positive.
  4. Chest imaging confirm COVID-19 featured lesions in lung.

Exclusion Criteria:

  1. Receive any clinical trial drug treatment for COVID-2019 within 30 days before the screening assessment;
  2. Severe liver disease (e.g., Child Pugh score >=C or AST> 5 times of the upper limit);
  3. Patients with known severe renal insufficiency (estimated glomerular filtration rate <=30mL / min/1.73 m2) or patients receiving continuous renal replacement therapy, hemodialysis, peritoneal dialysis;
  4. Co-infection of HIV, hepatitis B, tuberculosis, influenza virus, adenovirus or other respiratory infection viruses;
  5. Female patients who have no sexual protection in the last 30 days prior to the screening assessment;
  6. Pregnant or lactating women or women using estrogen contraception;
  7. Patients who are planning to become pregnant during the study period or within 6 months after the end of the study period;
  8. Other conditions that the researchers consider not suitable for participating in this clinical trial.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04336254


Contacts
Layout table for location contacts
Contact: Qingsong Ye, PhD,DDS +8615858242516 qingsongye@foxmail.com
Contact: Chenliang Zhou, PhD +862788041919 ext 83920

Locations
Layout table for location information
China, Hubei
Renmin Hospital of Wuhan University (East Campus) Recruiting
Wuhan, Hubei, China
Contact: Chenliang Zhou, PhD    +86 027 88041919 ext 83920      
Sponsors and Collaborators
Renmin Hospital of Wuhan University
Beijing SH Bio-Tech Corporation, Beijing (CN)
Utooth Biological Technology Co., Ltd. Hubei (CN)
Investigators
Layout table for investigator information
Study Chair: Prof. Qingsong Ye, PhD,DDS Center for Regenerative Medicine, Renmin Hospital of Wuhan University
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Ye Qingsong, Professor, Director, Renmin Hospital of Wuhan University
ClinicalTrials.gov Identifier: NCT04336254    
Other Study ID Numbers: 2020K-G005
hDPSC-CoVID-2019-02-2020 ( Other Identifier: Renmin Hospital of Wuhan University )
First Posted: April 7, 2020    Key Record Dates
Last Update Posted: March 10, 2021
Last Verified: March 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Ye Qingsong, Renmin Hospital of Wuhan University:
Cronovirus
Human Dental Pulp Stem Cells
Dental Stem Cell Banking
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Pneumonia, Viral
Pneumonia
Respiratory Tract Infections
Infections
Virus Diseases
 Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases